Recommendations for HER2 evaluation methods in breast cancers are published and periodically updated by a panel of experts to improve upon the accuracy and convenience of HER2 testing by immunohistochemistry (IHC) or Fluorescent In Situ Hybridization (FISH), which represent the gold standard in clinical practice7, 8. Here, ERBB2 is linked to breast carcinoma.